The glucose biosensors market size is estimated to be USD 13,279.5 million in 2022 and is expected to witness a CAGR of 14.45% during the forecast period 2023-2033. The increasing self-monitoring gadget demand, modernizations in glucose biosensor technology, and a growing proportion of people worldwide developing diabetes are factors contributing to the market growth. However, strict regulatory framework and the high price of glucose biosensors is expected to hinder the growth.

Segmentation

By Technology

On the basis of technology, the market is bifurcated into optical biosensors and electrochemical biosensors. In 2022, the electrochemical biosensors segment held the highest market share owing to its maintenance convenience, sensitivity, and durability.

By Product

Based on product, the market is bifurcated into self-monitoring blood glucose (SMBG), and continuous glucose monitoring (CGM). In 2022, the self-monitoring blood glucose (SMBG) segment held the highest market share owing to the availability of disease management and control tools, and increasing knowledge of the dangers and issues associated with diabetes.

By End User

On the basis of end user, the market is segregated into home care, hospitals, diagnostic centers & clinics, and others. In 2022, the hospitals segment held the highest market share owing to a rise in the number of diabetic patients attending hospitals, and the widespread usage of glucose biosensors in healthcare facilities.

Regional Markets

In 2022, North America region accounted for the highest revenue in the glucose biosensors market and is expected to maintain its dominance during the forecast period. This is attributed to the growing elderly population, diabetes’s rising prevalence in the region, surging demand for remote & home monitoring, increased incidence of diabetes brought on by lifestyle modifications, and improvements in technology. However, the Asia-Pacific region is predicted to grow at the fastest rate during the projection period owing to increasing public understanding of the benefits of early diagnosis to increase patient survival rates, growing incomes, accessibility of sophisticated glucose biosensors from a variety of vendors, and enhancements to healthcare facilities and payment procedures.

Competitor Insights

Some of the key players operating in the glucose biosensors market are Trividia Health (US), Sanofi (France), Nova Diabetes Care (USA), Lifescan (US), GlySens Incorporated (US), F. Hoffmann-La Roche Ltd (Switzerland), Dexcom (US), Bayer (Germany), Ascenia Diabetes Care (Switzerland), and Abbott Laboratories (US).

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including technology, product, and end user from 2023 to 2033.

Report Scope:

Segmentation: Glucose Biosensors Market Report 2022 – 2033

Technology (Revenue, USD Million), 2022 – 2033

• Optical Biosensors
• Electrochemical Biosensors

Product (Revenue, USD Million), 2022 – 2033

• Self-Monitoring Blood Glucose (SMBG)
• Continuous Glucose Monitoring (CGM)

End User (Revenue, USD Million), 2022 – 2033

• Home Care
• Hospitals
• Diagnostic Centres & Clinics
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA